News

While there are some exciting advances coming down the pipeline, there is still much work to do when it comes to the molecular diagnosis of patients with renal cell carcinoma (RCC), explained David I. Quinn, MBBS, PhD, FRACP, FACP.

Wells A. Messersmith, MD, co-director of the developmental therapeutics program at the University of Colorado Cancer Center, said work in this area is needed to fill the knowledge gaps in metastatic CRC, which has a 5-year survival rate of just 11%.

Check out this infographic exploring 5 ways oncology nurses can do their part to improve cancer care for their patients.

Oncology nurses must discuss treatment options and adverse events with their patients who have ovarian cancer.

Man’s best friend may eventually be healthcare’s best friend.

Team V raises thousands to support cancer research

Fourth-Generation, Family-Owned Egg and Feed Farm Joins Local Cycling Event to Achieve Victory Over Cancer®

The FDA has granted an approval to the combination of atezolizumab (Tecentriq) with carboplatin and etoposide for the frontline treatment of patients with extensive-stage small cell lung cancer (ES-SCLC).

An expert discusses the role oncology nurses play in managing the adverse events of patients with breast cancer.

Listen to the first-ever episode of the CURE Talks Cancer Podcast: Nursing Edition.

It’s an exciting time in the world of triple-negative breast cancer (TNBC), with treatments becoming more personalized to individual cancer subtypes, explained Adam Brufsky, MD, PhD.

Financial distress puts a major burden on patients with cancer and their families. And while there are numerous resources that nurses can share with their patients to help with co-pays and other money-related issues, they are not widely discussed.

Clinical trials can be very beneficial to patients and their families. However, barriers still exist in enrolling patients.

The FDA has granted an approval to PF-05280014 (Trazimera; trastuzumab-qyyp), a trastuzumab (Herceptin) biosimilar, to treat patients with HER2-overexpressing breast cancer as well as HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma

More patients are surviving long after their cancer diagnoses, putting a new emphasis on survivorship care planning, explained Deborah A. Boyle, MSN, RN, AOCNS, FAAN.

The FDA approved the VENTANA PD-L1 (SP142) Assay as the first companion diagnostic to aid in identifying patients with triple-negative breast cancer who are eligible for treatment with Tecentriq (atezolizumab) plus chemotherapy.

Rivaroxaban (Xarelto) significantly lowered the incidence of venous thromboembolism (VTE) or death due to VTE during the intervention period with the agent in patients with solid tumors or lymphoma, according to results from the CASSINI trial.

The Food and Drug Administration has granted an accelerated approval to the frontline combination of atezolizumab (Tecentriq) plus nab-paclitaxel (Abraxane) for patients with unresectable locally advanced or metastatic PD-L1–positive triple-negative breast cancer (TNBC)

Chemotherapy-induced nausea and vomiting (CINV) is a major issue in patients with blood cancers who are undergoing chemotherapy before receiving hematopoietic stem cell transplantation.

In an interview with Oncology Nursing News, Christopher R. Friese, PhD, RN, AOCN, FAAN, discussed his study, and though the results were not what he expected, Friese still emphasized the need for proper education for oncology nurses.

Alex Trebek, the long-time host of the popular game show Jeopardy!, announced that he was diagnosed with stage 4 pancreatic cancer.

The FDA has granted a priority review designation to a new drug application (NDA) for fedratinib as a treatment for patients with myelofibrosis.

Partnerships to Coincide with NCAA Basketball Tournaments

When handling chemotherapy and other potentially dangerous anti-cancer drugs, there are steps that oncology nurses should take to protect themselves and their colleagues, according to a recent presscast from the American Society of Clinical Oncology (ASCO).

The FDA has expanded the approval of aprepitant (Cinvanti) injectable emulsion to include a 2-minute intravenous (IV) use for the prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV).

Here are the top 5 Oncology Nursing News stories for February 2019.

A liquid biopsy test detected all of the guideline-recommended biomarkers in newly diagnosed patients with metastatic non-small cell lung cancer at a similar rate but faster turnaround time to that of tissue genotyping.

The FDA has approved subcutaneous use of trastuzumab (Herceptin) and hyaluronidase-oysk injection (Herceptin Hylecta) in combination with chemotherapy for the treatment of select patients with HER2-positive early breast cancer, and alone or in combination with paclitaxel in patients with metastatic HER2-positive breast cancer who have received at least 1 prior chemotherapy regimen.